Ocular Therapeutix
United States 333 employees Updated 9 July 2026
Ocular Therapeutix is a finished-dose manufacturer based in United States. It appears in 2 regulatory filings across 2 regulators, without an active US DMF or CEP on file. Its filings concentrate with US FDA and EMA. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 9 November 2023 as NAI.
1
registered plants
1 with an FDA FEI number
2
filings
across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 9 November 2023 NAI US FDA
- 11 February 2016 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Bedford, United States | 3008477155 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 1 | 1 |
| EMA | 1 | None |
Comparing suppliers?
Choose your molecules and target markets. Ocular Therapeutix comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was NAI, on 9 November 2023.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates